Molecular Medicine (Dec 2022)

Galantamine attenuates autoinflammation in a mouse model of familial mediterranean fever

  • Ibrahim T. Mughrabi,
  • Mahendar Ochani,
  • Mirza Tanovic,
  • Ping Wang,
  • Betty Diamond,
  • Barbara Sherry,
  • Valentin A. Pavlov,
  • Seza Ozen,
  • Daniel L. Kastner,
  • Jae Jin Chae,
  • Yousef Al-Abed

DOI
https://doi.org/10.1186/s10020-022-00571-9
Journal volume & issue
Vol. 28, no. 1
pp. 1 – 11

Abstract

Read online

Abstract Background Autoinflammatory diseases, a diverse group of inherited conditions characterized by excessive innate immune activation, have limited therapeutic options. Neuroimmune circuits of the inflammatory reflex control innate immune overactivation and can be stimulated to treat disease using the acetylcholinesterase inhibitor galantamine. Methods We tested the efficacy of galantamine in a rodent model of the prototypical autoinflammatory disease familial Mediterranean fever (FMF). Multiple chronic disease markers were evaluated in animals that received long-term galantamine treatment compared to vehicle. Results Long-term treatment with galantamine attenuated the associated splenomegaly and anemia which are characteristic features of this disease. Further, treatment reduced inflammatory cell infiltration into affected organs and a subcutaneous air pouch. Conclusions These findings suggest that galantamine attenuates chronic inflammation in this mouse model of FMF. Further research is warranted to explore the therapeutic potential of galantamine in FMF and other autoinflammatory diseases.

Keywords